Burning Rock Biotech Limited (BNR:NASDAQ) closed at $11.82 on October 23, 2026, down 10.79% on the day. The stock trades 71.7% below its 52-week high of $41.72 and 74.1% above its 52-week low of $6.79. Over the past year, it lost 9.5%. Burning Rock Biotech Limited is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, BNR closed higher on 124 days (49%). Its best day was January 22, 2026 (+32.20%) and its worst was March 13, 2026 (-29.93%). The stock moved 10% or more in a single session 42 times. It opened at least 5% above the previous day's high 2 times.
Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.
Find more stocks like BNR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.